Pharmaceutical composition
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- AEROTECH AUSTRALIA
- Filing Date
- 2026-05-20
- Publication Date
- 2026-07-17
Smart Images
Figure 00000000_0000_ABST
Abstract
Description
Abstract This application provides pharmaceutical compositions of magnesium salts with alpha-lipoic acid and / or methanesulfonylmethane (MSM), which can be used to treat, prevent, or reduce the severity of viral infections and / or skin conditions. Methods for preparing the pharmaceutical compositions and methods for using the pharmaceutical compositions in therapeutics are also provided.
Claims
CLAIMS1. A pharmaceutical composition comprising(a) a magnesium salt; and(b) lipoic acid and / or methylsulfonylmethane (MSM)2. The pharmaceutical composition of claim 1, wherein the magnesium salt is selected from the group consisting of magnesium chloride and magnesium sulphate.
3. The pharmaceutical composition of claim 1 or claim 2, wherein the composition is formulated for topical administration.
4. The pharmaceutical composition of any of claims 1 to 3, wherein the composition comprises magnesium chloride, alpha-lipoic acid and methylsulfonylmethane (MSM).
5. The pharmaceutical composition of any of claims 1 to 4, wherein the composition further comprises sodium bicarbonate.
6. The pharmaceutical composition of any of claims 1 to 5, wherein the composition is in the form of a liquid, an aqueous solution, a gel, a suspension, an emulsion, an ointment or a cream.
7. The pharmaceutical composition of any of claims 1 to 6, wherein the composition comprises by weight of the composition: 10%-65% magnesium sulphate, 5%-20% MSM, 5%-35% magnesium chloride, 1 %-10% sodium bicarbonate and / or 0.1 %-l % alpha-lipoic acid.
8. The pharmaceutical composition of any of claims 1 to 7, wherein the composition comprises 20%-50% by weight of the composition of magnesium chloride, alpha-lipoic acid, sodium bicarbonate, magnesium sulphate, and methylsulfonylmethane (MSM).
9. The pharmaceutical composition of any of claims 1 to 8, wherein the composition comprises lemon extract.
10. The pharmaceutical composition of any of claims 1 to 9, wherein the composition comprises 50%-80% by weight of lemon extract.
11. The pharmaceutical composition of any of claims 1 to 10, wherein the composition comprises an emollient, humectant, emulsifier, or preservative, or mixtures thereof.
12. The pharmaceutical composition of claim 11, wherein i) the emollient is selected from the group consisting of glyceryl stearate, ceteareth-20, ceteareth-12, cetearyl alcohol, cetyl palmitate, dimethicone, cyclopentasiloxane, cyclohexasiloxane, and caprylic / capric triglyceride, or a mixture thereof; ii) the humectant is selected from the group consisting of glycerol, glycerin, salicylic acid, and sorbitol, or a mixture thereof; ii) the emulsifier is selected from the group consisting of glyceryl stearate, ceteareth-20, ceteareth-12, cetearyl alcohol, and cetyl palmitate, or a mixture thereof; and iii) the preservative is selected from the group consisting of phenoxyethanol, ethylhexylglycerin, and sodium benzoate, or a mixture thereof.
13. A method of treating, preventing, or reducing the severity of a viral infection, or of a disease or disorder associated with a viral infection, or of a symptom of a viral infection, or of a symptom of a disease or disorder associated with a viral infection, in a subject, comprising administering an effective amount of a pharmaceutical composition according to any of claims 1 to 12 to the subject.
14. The method according to claim 13, wherein the viral infection, or disease or disorder associated with a viral infection, is selected from the group consisting of herpes zoster infection, varicella-zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidradenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia and SARS-CoV-2.
15. The method according to claim 13, wherein the symptom is selected from the group consisting of cracked skin, skin bleeding, skin peeling, skin redness and pain.
16. A method of treating, preventing, or reducing the severity of a disease or disorder, or of a symptom of a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of herpes zoster infection, varicella-zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidradenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia, pulmonary fibrosis and SARS- CoV-2, comprising administering an effective amount of a pharmaceutical composition according to any of claims 1 to 12 to the subject.
17. The method according to any of claims 13 to 16, wherein the composition is administered topically to the subject.
18. The method according to any of claims 13 to 17, wherein the composition is applied to the skin of the subject once daily, twice daily, or three times daily.
19. The method according to claim 18, wherein the topical composition is applied once per day.
20. The method according to any of claims 13 to 19, wherein the composition is applied as a spray, cream or liquid.
21. The method according to any of claims 13 to 16, wherein the composition is administered to the subject by inhalation.
22. Use of a pharmaceutical composition according to any of claims 1 to 12 for the manufacture of a medicament for treating, preventing, or reducing the severity of a viral infection, or of a disease or disorder associated with a viral infection, or of a symptom of a viral infection, or of a symptom of a disease or disorder associated with a viral infection.
23. The use according to claim 22, wherein the viral infection, or disease or disorder associated with a viral infection, is selected from the group consisting of herpes zoster infection, varicella-zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidr adenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia and SARS-CoV-2.
24. The use according to claim 22, wherein the symptom is selected from the group consisting of cracked skin, skin bleeding, skin peeling, skin redness and pain.
25. Use of a pharmaceutical composition according to any of claims 1 to 12 for the manufacture of a medicament for treating, preventing, or reducing the severity of a disease or disorder, or of a symptom of a disease or disorder, wherein the disease or disorder is selected from the group consisting of herpes zoster infection, varicella-zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidradenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia, pulmonary fibrosis and SARS- CoV-2.
26. The use according to any of claims 22 to 25, wherein the composition is administered topically.
27. The use according to any of claims 22 to 26, wherein the composition is applied to the skin ofa subject once daily, twice daily or three times daily.
28. The use according to claim 27, wherein the topical composition is applied once per day.
29. The use according to any of claims 22 to 28, wherein the composition is applied as a spray, cream or liquid.
30. The use according to any of claims 22 to 25, wherein the composition is administered to the subject by inhalation.
31. A pharmaceutical composition according to any of claims 1 to 12, for use in treating, preventing, or reducing the severity of a viral infection, or of a disease or disorder associated with a viral infection, or of a symptom of a viral infection, or of a symptom of a disease or disorder associated with a viral infection.
32. The pharmaceutical composition for use according to claim 31, wherein the viral infection, or disease or disorder associated with a viral infection, is selected from the group consisting of herpes zoster infection, varicella-zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidradenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia and SARS-CoV-2.
33. The pharmaceutical composition for use according to claim 31, wherein the symptom is selected from the group consisting of cracked skin, skin bleeding, skin peeling, skin redness and pain.
34. A pharmaceutical composition according to any of claims 1 to 12, for use in treating, preventing, or reducing the severity of a disease or disorder, or of a symptom of a disease or disorder, wherein the disease or disorder is selected from the group consisting of herpes zoster infection, varicella-zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidradenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia, pulmonary fibrosis and SARS-CoV-2.
35. A pharmaceutical composition for use according to any of claims 31 to 34, wherein the composition is administered topically.
36. A pharmaceutical composition for use according to any of claims 31 to 35, wherein the composition is applied to the skin of a subject once daily, twice daily or three times daily.
37. A pharmaceutical composition for use according to claim 36, wherein the topical composition is applied once per day.
38. A pharmaceutical composition for use according to any of claims 31 to 37, wherein the composition is applied as a spray, cream or liquid.
39. The use according to any of claims 31 to 34, wherein the composition is administered to the subject by inhalation.
40. A pharmaceutical composition according to any of claims 1 to 12 when used in treating, preventing, or reducing the severity of a viral infection, or of a disease or disorder associated with a viral infection, or of a symptom of a viral infection, or of a symptom of a disease or disorder associated with a viral infection.
41. The pharmaceutical composition when used according to claim 40, wherein the viral infection, or disease or disorder associated with a viral infection, is selected from the group consisting of herpes zoster infection, varicella- zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidradenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia and SARS-CoV-2.
42. The pharmaceutical composition when used according to claim 40, wherein the symptom is selected from the group consisting of cracked skin, skin bleeding, skin peeling, skin redness and pain.
43. A pharmaceutical composition according to any of claims 1 to 12 when used in treating, preventing, or reducing the severity of a disease or disorder, or of a symptom of a disease or disorder, wherein the disease or disorder is selected from the group consisting of herpes zoster infection, varicella-zoster infection, herpes simplex infection, chicken pox, shingles, cold sores, genital herpes, hidradenitis suppurativa, psoriasis, acne, atopic dermatitis, atopic eczema, postherpetic neuralgia, pulmonary fibrosis and SARS-CoV-2.
44. A pharmaceutical composition when used according to any of claims 40 to 43, wherein the composition is administered topically.
45. A pharmaceutical composition when used according to any of claims 40 to 44, wherein the composition is applied to the skin of a subject once daily twice daily or three times daily.
46. A pharmaceutical composition when used according to claim 45, wherein the topical composition is applied once per day.
47. A pharmaceutical composition when used according to any of claims 40 to 46, wherein the composition is applied as a spray, cream or liquid.
48. A pharmaceutical composition when used according to any of claims 40 to 43, wherein the composition is administered to the subject by inhalation.
49. A method of making a pharmaceutical composition according to any of claims 1 to 12, the method comprising: combining a magnesium salt with methysulfonylmethane (MSM) and / or alpha-lipoic acid to form a mixture; and combining the mixture with water or an aqueous solution.
50. The method according to claim 47, wherein the method comprises:(i) combining magnesium sulphate, methylsulfonylmethane (MSM), alpha-lipoic acid and sodium bicarbonate,(ii) adding magnesium chloride to the product of step (i) to form a mixture,(iii) combining the mixture formed in step (ii) with water or an aqueous solution.
51. The method according to claim 50, wherein the mixture formed in step (ii) comprises by weight of the composition: 10%-55% magnesium sulphate, 5%-20% MSM, 5%-30% magnesium chloride, l%-10% sodium bicarbonate and O.1%-1% alpha-lipoic acid.
52. The method according to any of claims 49 to 51, wherein the pharmaceutical composition comprises 20%-50% by weight of the composition of magnesium chloride, alpha-lipoic acid, sodium bicarbonate, magnesium sulphate, and methylsulfonylmethane (MSM), and 50%-80% by weight of water or an aqueous solution.
53. The method according to any of claims 49 to 52, wherein an aqueous solution is added, and wherein the aqueous solution comprises lemon extract.
54. The method according to claim 53, wherein the lemon extract is lemon juice.